Bank of America cuts InterContinental Hotels price target to 10,200 (10,300) pence - 'buy' Comments and questions to [email protected] Copyright 2025 Alliance News Ltd. All Rights Reserved.

Investing.com - Scotiabank (TSX: BNS) downgraded Sage (LON: SGE) Therapeutics (NASDAQ: SAGE) from Sector Outperform to Sector Perform on Tuesday, while lowering its price target to $9.20 from $12.00.

See the latest UBS Group AG Registered Shares stock price (UBS:XNYS), related news, valuation, dividends and more to help you make your investing decisions.

UBS Wealth Advice Center. Helping advisors gain 19% new business growth through personalized wealth advice for HNW clients while earning ongoing compensation.

This year marks 160 years of UBS. From the foundation of our three keys to success to today’s forward-looking strategy: we’ve achieved a lot. Everything we do and have today is built on the history ...

The latest international UBS Group AG news and views from Reuters - one of the world's largest news agencies ...

Sage Therapeutics has agreed to be acquired by Supernus Pharma in a deal valued at around $571 million, bringing together two companies working on central nervous system therapies that have ...

Biogen has offered to buy all the shares in Sage Therapeutics that it doesn't already own, taking control of their novel antidepressant Zurzuvae. The $7.22-per-share deal for 89.8% of Sage is a 30 ...